TAHL CINDY 4

What Happened Cindy Tahl, Chief Legal and Compliance Officer of Fate Therapeutics (FATE), reported a sale of 25,590 shares on 2026-05-20. The shares were sold at a weighted average price of $1.88 per share for total proceeds of approximately $48,084. The filing indicates these shares were sold automatically as a sell-to-cover to satisfy tax withholding in connection with the vesting of 50,000 performance-based RSUs granted on July 29, 2024 — the sales were executed pursuant to an irrevocable election and not at the Reporting Person’s discretion.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (appears timely).
• Shares sold: 25,590 at a weighted avg price $1.88; price range reported $1.835–$1.935.
• Proceeds: ≈ $48,084.
• Reason: Sell-to-cover to satisfy tax withholding on vesting of 50,000 performance-based RSUs (footnote F1). Sales were automatic per an irrevocable election (F1).
• Filing notes (F2): weighted average and price range; issuer or Commission staff can request per-price breakdown.
• Shares owned after the transaction: not specified in this Form 4.

Context This was a routine tax-withholding sale tied to RSU vesting (a common event) rather than a discretionary market sell. Such sell-to-cover transactions are administrative and don’t necessarily signal the insider’s view on the company’s prospects. Purchases or discretionary sales are typically more informative about insider sentiment.